Prognostic value and clinical significance of long noncoding RNA CASC2 in human malignancies: a meta-analysis
Authors Cai J, Zuo X, Chen Z, Zhao W, Zhu Y, Zhang Z, Ye X
Received 3 January 2018
Accepted for publication 22 March 2018
Published 31 May 2018 Volume 2018:10 Pages 1403—1412
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Lu-Zhe Sun
Juan Cai,1,* Xueliang Zuo,2,* Zhiqiang Chen,3,4,* Wenying Zhao,1 Yiping Zhu,1 Zhengxiang Zhang,1 Xiaobing Ye1
1Department of Oncology, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China; 2Department of Gastrointestinal Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China; 3Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; 4Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China
*These authors contributed equally to this work
Purpose: This meta-analysis aimed to assess the prognostic value of long noncoding RNA cancer susceptibility candidate 2 (CASC2) in human tumors.
Materials and methods: We searched the available databases up to December 2017. Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were used to examine the prognostic impact of CASC2 on overall survival (OS) in patients diagnosed with malignancies.
Results: A total of eight studies with 663 cancer patients were enrolled. Our results showed that high CASC2 expression level was associated with a favorable OS (HR=0.437, 95% CI: 0.345–0.554). The significant results were not altered by stratified analysis according to cancer type, sample size, follow-up months, and HR estimation method. A significant association of glioma tumor stage with CASC2 expression was detected (III–IV vs I–II: odds ratio=2.126, 95% CI: 1.032–4.378). CASC2 could be used as an independent prognostic factor for OS (HR=0.450, 95% CI: 0.336–0.602). Sensitivity analysis showed that no single study changed the pooled results significantly. Begg’s funnel plot and Egger’s test showed that no publication bias was detected.
Conclusion: High expression level of CASC2 is associated with favorable survival outcome for cancer patients, and CASC2 could be used as a prognostic predictor for cancers.
Keywords: CASC2, long noncoding RNA, prognosis, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]